Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A

This publication has 55 references indexed in Scilit:

• Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy
  American Journal of Hematology, 2001
• Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2‐year review
  Haemophilia, 2001
• Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients
  Seminars in Thrombosis and Hemostasis, 2000
• Advances toward Gene Therapy for Hemophilia at the Millennium
  Human Gene Therapy, 1999
• Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates
  Haemophilia, 1999
• German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies
  Haemophilia, 1999
• WHY DO SO MANY HAEMOPHILIA A PATIENTS DEVELOP AN INHIBITOR?
  British Journal of Haematology, 1995
• Development of Factor VIII Antibody in Haemophilic Monozygotic Twins
  Scandinavian Journal of Haematology, 1979
• CHARACTERIZATION OF FACTOR VIII ANTIBODIES
  Annals of the New York Academy of Sciences, 1975
• A Factor VIII Inhibitor in a Mild Hemophiliac
  The Lancet Healthy Longevity, 1970